Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer

Highlights • Autoantibodies to BIRC5 and MYC were measured in cervical cancer patients and a control group. • There was a significant difference in circulating levels of these autoantibodies in the patient and control groups. • ROC analysis suggests that anti-BIRC5 IgG has a higher sensitivity than anti-MYC IgG. • Anti-BIRC5 IgG could serve as a biomarker for the early diagnosis of cervical cancer.
The present study was undertaken to detect circulating IgG antibodies to peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II, and 130 healthy female subjects were recruited for analysis of circulating IgG antibodies to BIRC5 and MYC. Student’s t-test showed significant differences in circulating levels of anti-BIRC5 IgG (t = −4.27, df = 235, P